secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-09-15T23:59:59+00:00
Accession:  0001558370-22-014430
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xilio appoints Tomas Heyman to Board of Directors
-------------------------------------------------

- Tomas Heyman appointed as Class I director effective September 15, 2022.
- He will serve until the 2025 annual meeting or until earlier resignation.
- Appointed to Nominating and Corporate Governance Committee and Audit Committee.
- Compensation follows standard non-employee director arrangements as disclosed in 2022 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/xlo-20220915x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-014430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer